Zealand Pharma

Zealand Pharma is the Danish biotech that nobody outside Copenhagen took seriously until 2024 — and now it is the third name on every obesity-investor whiteboard after Novo Nordisk and Eli Lilly. The market cap of DKK 22 bn sits on a single platform bet: peptide engineering across GLP-1, amylin, glucagon and combinations of all three.

The headline asset is petrelintide, a long-acting amylin analog currently in three Phase 3 trials (ZUPREME-1, ZUPREME-2, ZUPREME-T2D). Amylin co-administered with GLP-1 hit weight-loss numbers in mid-stage trials comparable to tirzepatide but with a substantially better tolerability profile — far less nausea, less muscle-mass loss. If Phase 3 readouts confirm this in H2/2026, Zealand becomes the only company with a credible second-mechanism obesity asset.

The second leg is the survodutide deal with Boehringer Ingelheim — Zealand keeps 50% of the economics on a dual GLP-1/glucagon agonist that has already shown best-in-class MASH-resolution data (83% in F2/F3 fibrosis). Boehringer files for both obesity and MASH indications in 2026.

Institutional ownership is heavily Northern-European: Novo Holdings (the foundation behind Novo Nordisk) held 5.8% via the Novo Capital Investors arm as of Q1/2026 — an unusual cross-holding given direct competition. RBC Capital and BlackRock each above 3%. No US-celebrity hedge fund has filed a 13F position large enough to disclose, though Baker Bros and Perceptive Advisors are rumored buyers based on EPFR flow data.

The most interesting smart-money signal is insider activity: chair Alf Martin Johansen bought DKK 4.2 M of shares at DKK 285-310 between February and April 2026 — his first open-market purchases since the IPO. CFO Henriette Wennicke exercised options and held all shares rather than selling.

Short interest peaked at 8.2% in November 2025 (pre-survodutide MASH data) and has collapsed to 2.1% post the Boehringer milestone payment of EUR 130 M in January 2026.

Forward P/E of 38.4x means little for a biotech with rapidly compounding R&D-driven losses — the relevant metric is risk-adjusted NPV. SEB models the total platform at DKK 28-46 bn under base/bull cases (current cap DKK 22 bn), Jefferies at DKK 35 bn, BofA at DKK 30 bn. The implied probability of petrelintide approval embedded in the share price is roughly 45% — historical Phase 3 obesity approval rates run 65-75%, so the market is discounting a higher-than-average failure rate. EV/Peak-Sales (Zealand share) sits at 1.4x against a peer median of 2.1x for partnered or single-asset obesity biotechs.

1. Q3 2026: Dapiglutide Phase 2 obesity data (GLP-1/GLP-2 weekly dosing)
2. November 2026: ZUPREME-1 petrelintide Phase 3 28-week interim data — primary stock-moving event
3. H2 2026: Boehringer Ingelheim survodutide regulatory filings for obesity and MASH

Zealand Pharma is the European obesity bet for investors who think the Novo/Lilly duopoly will not stay a duopoly forever. The setup is unusual: a single binary event (ZUPREME-1) determines whether the next 24 months are a triple or a halving. I would not own this as a core position — the asymmetry only works if you size it small enough that a 50% drawdown does not kill the portfolio. My personal approach is to size at 1-2% of equity exposure with a defined stop at DKK 220, planning to add aggressively on a clean Phase 3 readout. The boring catch is that even success leads to dilution before it leads to revenue — so do not expect a one-week rerating.